BRILLIANT-SC: A Study of the Efficacy and Safety of Blisibimod Administration in Subjects With IgA Nephropathy

Inclusion Criteria: * 18 years of age or older. * Biopsy-proven IgA nephropathy * Proteinuria ≥ 2g/24hr or equivalent * Receiving physician-directed optimized standard of care that includes ACEI and/or ARB. * Estimated glomerular filtration rate (eGFR) \>40mL/min/1.73m2 Exclusion Criteria: * Clinical or histologic evidence of non-IgA-related glomerulonephritis * IgA nephropathy with greater than 50% glomerulosclerosis or cortical scarring * Meets eGFR criteria * Malignancy within past 5 years * Known to be positive for HIV and/or positive at the screening visit for hepatitis B, or hepatitis C * Liver disease * Neutropenia * Active infection requiring hospitalization or treatment with parenteral antibiotics within the past 60 days or history of repeated herpetic viral infections * History of active tuberculosis or a history of tuberculosis infection * Pregnant or nursing